公开(公告)号：US12209090B2

公开(公告)日：2025-01-28

申请号：US17430876

申请日：2020-02-14

Applicant: Centre National de la Recherche Scientifique ,  Université de Strasbourg ,  ETAT FRANCAIS (Ministère des armées), representé par la Direction Centrale du Service de Santé des Armées

Inventor： Rachid Baati ,  Richard Brown ,  José Dias ,  Alex Maryan-Instone ,  Jagadeesh Yerri

IPC: C07D473/34 ,  A61P25/00 ,  C07D213/42 ,  C07D213/78 ,  C07D401/06 ,  C07D473/02 ,  C07D519/00

Abstract: The present invention relates to a compound of formula (I), or one of its pharmaceutically acceptable salts: (I) wherein R1, R2 and —X—Y— have specific definitions. It also relates to the use of such a compound in therapy; and to a process for preparing it.

公开(公告)号：US20220081442A1

公开(公告)日：2022-03-17

申请号：US17430876

申请日：2020-02-14

Applicant: Centre National de la Recherche Scientifique ,  Université de Strasbourg ,  ETAT FRANCAIS (Ministère des armées), representé par la Direction Centrale du Service de Santé des

Inventor： Rachid BAATI ,  Richard BROWN ,  José DIAS ,  Alex MARYAN-INSTONE ,  Jagadeesh YERRI

IPC: C07D473/34 ,  C07D213/42 ,  C07D401/06 ,  C07D519/00 ,  C07D473/02

Abstract: The present invention relates to a compound of formula (I), or one of its pharmaceutically acceptable salts: (I) wherein R1, R2 and —X—Y— have specific definitions. It also relates to the use of such a compound in therapy; and to a process for preparing it.

公开(公告)号：US20200246286A1

公开(公告)日：2020-08-06

申请号：US16843215

申请日：2020-04-08

Applicant: The University of Melbourne

Inventor： Paul Stephen DONNELLY ,  Stacey Erin RUDD ,  Spencer John WILLIAMS

IPC: A61K31/18 ,  C07K17/06 ,  A61K51/10 ,  C07C259/06 ,  C07C309/14 ,  C07C311/19 ,  C07C311/29 ,  C07C311/42 ,  C07C311/46 ,  C07C323/60 ,  C07D207/48 ,  C07D211/60 ,  C07D211/96 ,  C07D213/42 ,  C07D213/74 ,  C07D213/89 ,  C07D215/36 ,  C07D223/06 ,  C07D277/06 ,  C07D277/80 ,  C07D279/12 ,  C07D295/13 ,  C07D309/06 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D453/06 ,  C07D471/08 ,  C07D487/08

Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.

公开(公告)号：US10398660B2

公开(公告)日：2019-09-03

申请号：US15963599

申请日：2018-04-26

Applicant: The University of Melbourne

Inventor： Paul Stephen Donnelly ,  Stacey Erin Rudd ,  Spencer John Williams

IPC: A61K31/18 ,  A61K51/10 ,  C07C259/06 ,  C07C309/14 ,  C07C311/19 ,  C07C311/29 ,  C07C311/42 ,  C07C311/46 ,  C07C323/60 ,  C07D207/48 ,  C07D211/60 ,  C07D211/96 ,  C07D213/42 ,  C07D213/74 ,  C07D213/89 ,  C07D215/36 ,  C07D223/06 ,  C07D277/06 ,  C07D277/80 ,  C07D279/12 ,  C07K17/06 ,  C07D295/13 ,  C07D309/06 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D453/06 ,  C07D471/08 ,  C07D487/08

Abstract: The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal center, particularly for the imaging of tumors.

公开(公告)号：US20190177275A1

公开(公告)日：2019-06-13

申请号：US16308128

申请日：2017-06-09

Applicant: The Johns Hopkins University

Inventor： Hayden T. Ravert ,  Daniel P. Holt ,  Ying Chen ,  Ronnie C. Mease ,  Hong Fan ,  Martin G. Pomper ,  Robert F. Dannals

IPC: C07D213/42 ,  A61P35/00 ,  A61K51/04 ,  C07B59/00

Abstract: Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.

公开(公告)号：US10196373B2

公开(公告)日：2019-02-05

申请号：US14452183

申请日：2014-08-05

Applicant: University of Central Florida Research Foundation, Inc. ,  THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

Inventor： James Turkson ,  Patrick Gunning

IPC: C07D239/02 ,  C07D401/04 ,  A61K31/18 ,  C07C311/19 ,  C07C311/29 ,  C07C311/42 ,  C07C323/49 ,  C07D207/48 ,  C07D211/26 ,  C07D211/96 ,  C07D213/42 ,  C07D215/36 ,  C07D233/84 ,  C07C311/46 ,  C07D211/34 ,  C07D211/60

Abstract: In one aspect, the invention relates to substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs, derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20180312468A1

公开(公告)日：2018-11-01

申请号：US15963450

申请日：2018-04-26

Applicant: The Procter & Gamble Company

Inventor： Guiru Zhang ,  Stephanie Lee Davis ,  Bryan Patrick Murphy ,  David Salloum

IPC: C07D213/42 ,  C07D213/34 ,  A61Q5/04 ,  A61Q9/04

CPC classification number: C07D213/32 ,  A61K8/4926 ,  A61Q5/04 ,  C07D213/74

Abstract: Described herein is a chemical class of odorless thiols which can serve as reducing agents. This chemical class involves thiols which can be used as reducing agents for permanent styling treatments, depilatory compositions and other applications. The odorless thiols are thiols having a heterocyclic quaternary ammonium salt in their molecule.

公开(公告)号：US20180127361A1

公开(公告)日：2018-05-10

申请号：US15681309

申请日：2017-08-18

Applicant: JANSSEN SCIENCES IRELAND UC

Inventor： Koen VANDYCK ,  Stefaan Julien LAST ,  Geert ROMBOUTS ,  Wim Gaston VERSCHUEREN ,  Pierre Jean-Marie Bernard RABOISSON

IPC: C07C311/37 ,  C07C311/14 ,  C07D205/04 ,  A61K45/06 ,  A61K31/401 ,  A61K31/495 ,  C07D233/84 ,  A61K31/34 ,  A61K31/397 ,  C07D309/14 ,  A61K31/5375 ,  A61K31/55 ,  C07D223/06 ,  C07D307/68 ,  C07D295/26 ,  C07D211/76 ,  C07D211/56 ,  C07D295/13 ,  C07D211/28 ,  C07D277/56 ,  C07D207/36 ,  C07D493/08 ,  C07D207/14 ,  C07D491/107 ,  C07D233/90 ,  C07D333/48 ,  C07D333/38 ,  C07D213/82 ,  C07D213/81 ,  C07D307/22 ,  C07D305/08 ,  C07D211/96 ,  C07C311/51 ,  C07C311/20 ,  C07C311/16 ,  A61K31/4468 ,  A61K31/4453 ,  A61K31/44 ,  A61K31/426 ,  A61K31/4164 ,  A61K31/351 ,  A61K31/341 ,  A61K31/337 ,  A61K31/18 ,  C07D307/60 ,  C07D213/42 ,  C07D207/273

Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

公开(公告)号：US20170360041A1

公开(公告)日：2017-12-21

申请号：US15634284

申请日：2017-06-27

Applicant: MEIJI SEIKA PHARMA CO., LTD.

Inventor： Shinzo KAGABU ,  Masaaki MITOMI ,  Shigeki KITSUDA ,  Ryo HORIKOSHI ,  Masahiro NOMURA ,  Yasumichi ONOZAKI

IPC: A01N43/40 ,  A01N37/18 ,  C07D417/12 ,  C07D405/12 ,  C07D401/12 ,  C07D401/06 ,  C07D333/20 ,  C07D277/32 ,  C07D237/08 ,  C07D213/75 ,  C07D213/61 ,  C07D213/42 ,  C07D213/40 ,  C07D213/36 ,  C07D211/98 ,  C07C311/09 ,  C07C271/12 ,  C07C261/04 ,  C07C233/12 ,  C07C233/05 ,  A01N57/32 ,  A01N47/40 ,  A01N47/12 ,  A01N47/02 ,  A01N43/78 ,  A01N43/58 ,  A01N43/54 ,  A01N43/50 ,  C07F9/58

CPC classification number: A01N43/40 ,  A01N37/18 ,  A01N43/50 ,  A01N43/54 ,  A01N43/58 ,  A01N43/78 ,  A01N47/02 ,  A01N47/12 ,  A01N47/40 ,  A01N57/32 ,  C07C233/05 ,  C07C233/12 ,  C07C261/04 ,  C07C271/12 ,  C07C311/09 ,  C07D211/98 ,  C07D213/36 ,  C07D213/40 ,  C07D213/42 ,  C07D213/61 ,  C07D213/75 ,  C07D237/08 ,  C07D277/32 ,  C07D333/20 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07F9/58

Abstract: A compound of formula (Ie′): wherein Ar′, R1, R4e and Y are as defined herein and a method of controlling pests using the compound.

公开(公告)号：US09718760B2

公开(公告)日：2017-08-01

申请号：US14439843

申请日：2013-10-31

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN ,  EASTERN MICHIGAN UNIVERSITY

Inventor： Daniel A. Lawrence ,  Cory Emal ,  Ashley Reinke ,  Shih-Hon Li ,  Mark Warnock ,  Gregory Abernathy

IPC: C07C243/26 ,  C07C69/84 ,  C07C259/06 ,  C07C271/16 ,  C07C275/64 ,  C07C311/17 ,  C07C311/29 ,  C07C311/48 ,  C07C311/49 ,  C07D417/04 ,  C07C323/60 ,  C07D249/08 ,  C07C233/13 ,  C07C233/56 ,  C07D261/18 ,  C07C235/34 ,  C07C235/46 ,  C07D271/113 ,  C07D277/34 ,  C07D207/48 ,  C07C251/76 ,  C07D209/08 ,  C07D209/34 ,  C07D213/42

CPC classification number: C07D417/10 ,  C07C69/84 ,  C07C69/94 ,  C07C233/13 ,  C07C233/56 ,  C07C235/34 ,  C07C235/46 ,  C07C235/80 ,  C07C237/20 ,  C07C243/26 ,  C07C251/76 ,  C07C259/06 ,  C07C271/16 ,  C07C275/64 ,  C07C311/17 ,  C07C311/29 ,  C07C311/37 ,  C07C311/48 ,  C07C311/49 ,  C07C323/60 ,  C07D207/48 ,  C07D209/08 ,  C07D209/34 ,  C07D213/42 ,  C07D249/08 ,  C07D261/18 ,  C07D271/113 ,  C07D277/34 ,  C07D417/04

Abstract: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.